Lung Cancer Symptom Assessment and Management Intervention

Study summary

The purpose of this study is to develop and test the usability of a computerized symptom assessment and management intervention system in a laboratory setting (phase I) and its feasibility in a clinical setting in a group randomized trial (phase II).

Ask AI to explain this study

Start here

Key things to know

Main goalSupportive Care

This describes the study’s primary purpose.

What is being studiedSAMI

The study team can explain what participation involves.

Who it may be forLung Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 21, 2016 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?Dana-Farber Cancer Institute

Study sponsor

Study overview

What this study is about

Purpose: Supportive Care
Study type: Interventional
Phase: Phase 2
Sponsor: Dana-Farber Cancer Institute
Interventions being studied: Behavioral: SAMI

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Supportive or behavioral care→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

HCPs: attending physician, thoracic medical oncologist, expected to work in the setting for at least 2 years.
Patients: 21 years of age or older; diagnosis of Stage IIIA, IIIB, IV non-small cell lung cancer OR limited or extensive stage small cell lung cancer; receiving care in the out-patient setting; receiving treatment with chemotherapy +/- additional therapies; English speaking.

Reasons someone may not be able to joinExclusion criteria

Patients: Any patient who needs emergent care, routine visits scheduled less than once a month

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Dana-Farber Cancer InstituteBoston, Massachusetts
Boston Medical CenterBoston, Massachusetts

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 21, 2016. Always confirm current availability with the study team.

View original record ↗